GenScript Biotech adds 400,000 square-feet of single RNA and non-viral DNA manufacturing capacity at its site in Zhenjiang, China to support biopharma cell and gene therapy (CGT) projects.
The recently operational five-story 400,000 square-foot plant in Zhenjiang offers multiple segregated manufacturing and purification cleanrooms, Kay Huang, head of marketing at GenScript Biotech USA, said. “This new expansion will allow us to deliver GMP materials faster and help expedite our clients’ project timelines.” No financial details were divulged.
“The demand come from clients using CRISPR technology or other gene-editing tools for developing gene and cell therapeutics,” we were told.
DepositPhotos/[email protected]
“For gene insertion, correction or replacement, CRISPR sgRNA [single RNA] and payloads for gene delivery are needed. With the rapid development we are seeing in this field, more projects are moving into the clinical phase, yet the availability of cGMP reagents are limited. The goal of these new expanded lines is to help gene- and cell-therapy clients move their research into clinical studies faster.”
The facility complements the five manufacturing lines at its facility in Nanjing, established by GenScript in 2021.